Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with Stage II or Stage III invasive breast cancer that has not spread to other parts of the body, and who have not yet received any treatment for it
- People whose breast cancer tests show low or no estrogen receptor activity (10% or less), low or no progesterone receptor activity (10% or less), and is HER2-negative (confirmed by specific lab testing methods)
- People who have not previously received chemotherapy, hormone therapy, or immunotherapy of any kind
- People who are able and willing to attend scheduled visits, follow the study plan, complete required lab tests, and follow study rules throughout the trial
- People who have read and signed an informed consent form, showing they understand their diagnosis, the experimental nature of the treatment, the procedures involved, the risks, and the alternatives
Who may not be able to join:
- People who are pregnant, breastfeeding, or who are not willing to use birth control during the study
- People who have taken part in another clinical trial or used an experimental medical device within 21 days before the first dose of the study drugs
- People who are currently taking steroid medications (such as prednisone or dexamethasone) that are not part of the standard medications already included in the study treatment plan
- People who have had a serious allergic reaction to medicines that are chemically or biologically similar to the drugs used in this trial
- People who have uncontrolled health conditions, including active or ongoing infections, heart failure, unstable chest pain, irregular heart rhythms, or mental health or personal circumstances that could make it difficult to follow the study requirements
- People who are HIV-positive and currently taking combination antiretroviral therapy, due to the risk of dangerous drug interactions and increased risk of serious infection during treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ruth Sacks, MD, Emory University Hospital/Winship Cancer Institute
Phone: 404-778-1900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in the cytokine milieu in the blood
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.